TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Luca Gianni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.